Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
4,766
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,094.90 | 27.60 | -0.30% |
CAC 40 | 7,786.98 | 31.24 | -0.40% |
DAX 40 | 23,359.18 | 29.94 | 0.13% |
Dow JONES (US) | 46,018.32 | 260.42 | 0.57% |
FTSE 100 | 9,208.37 | 12.71 | 0.14% |
HKSE | 26,908.39 | 469.88 | 1.78% |
NASDAQ | 22,261.33 | 72.63 | -0.33% |
Nikkei 225 | 44,790.38 | 111.89 | -0.25% |
NZX 50 Index | 13,228.38 | 6.51 | -0.05% |
S&P 500 | 6,600.35 | 6.41 | -0.10% |
S&P/ASX 200 | 8,818.50 | 30.00 | -0.34% |
SSE Composite Index | 3,876.34 | 14.48 | 0.37% |